Health
New VERTIS-CV data: Kidney function preserved with ertugliflozin in type 2 diabetes – Healio
New exploratory analyses show treatment with the SGLT2 inhibitor ertugliflozin reduced risk for worsening kidney function, dialysis or renal death among adults with type 2 diabetes compared with placebo.In prespecified exploratory analyses presented at the vi…
Source/Disclosures
Source: Cherney D. VERTIS-CV Outcome. Presented at: EASD Annual Meeting; Sept. 21-25, 2020 (virtual meeting).
Disclosures:
Merck and Pfizer sponsored VERTIS-CV. Cannon reports he has received research grants or honoraria from Aegerion, Alnylam, Amarin, Amgen, Applied Therapeutics, Ascendia, Boehringer Ingelheim, Bristol-Myers Squibb, Corvidia, Daiichi Sankyo, HLS Therapeutics, Innovent, Janssen, Kowa, Merck, Pfizer and Sanofi. Cherney reports he has received consultant f…
-
General22 hours agoThe ABC and Ms Lattouf
-
General21 hours agoHuman remains located, police make arrest in search for Sunbury man Joshua Bishop
-
General19 hours agoNetanyahu denounces report IDF soldiers had orders to shoot Gaza aid-seekers
-
General22 hours ago‘Heartbreaking’ algal bloom hits metropolitan Adelaide beaches